Amgen lipid-lowering drug meets phase three endpoints
Evolocumab, Amgen's human monoclonal antibody for the treatment of a genetic cause of high cholesterol, has performed well in a phase three trial.
Evolocumab, in combination with statins and other lipid-lowering therapies, met its primary endpoints in the trial in patients with heterozygous familial hypercholesterolemia - giving reductions in low-density lipoprotein cholesterol levels at ten and 12 weeks.
Sean Harper, executive vice-president of R&D, Amgen
Related news:
Amgen readies cholesterol drug after results from trial (Bloomberg).
Amgen's cholesterol fighter succeeds in fifth late-stage study (Reuters).
Reference links:
Amgen announces positive top-line results from phase 3 RUTHERFORD-2 trial of evolocumab (AMG 145) in patients with heterozygous familial hypercholesterolemia (Amgen press release).
